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ABSTRACT 
BACKGROUND: Previous studies have reported a high frequency of hepatocellular carcinoma 
(HCC) occurrence in patients with advanced liver disease, after receipt of interferon(IFN)-free therapy 
for hepatitis C virus (HCV) infection. Our objective was to verify and account for this phenomenon 
using data from the Scottish HCV Clinical Database. 
METHODS: We identified HCC-naïve individuals with liver cirrhosis receiving a course of antiviral 
therapy in Scotland from 1997-2016 resulting in a SVR. Patients were followed-up from their 
treatment start date to the earliest of: date of death, date of HCC occurrence, or Jan 2017. We used 
Cox regression to compare the risk of HCC occurrence according to treatment regimen after adjusting 
for relevant co-factors (including: demographic factors; baseline liver disease stage; 
comorbidities/health behaviours, virology, and previous treatment experience). HCC occurrence was 
ascertained through the both the HCV clinical database and medical chart review. For our main 
analysis, treatment regimen was defined as IFN-free versus IFN-containing.  
RESULTS: 857 patients met the study criteria, of whom 31.7% received an IFN-free regimen. 
Individuals receiving IFN-free therapy were more likely to be: older; of white ethnicity, Child-
Turcotte-Pugh B/C vs. Child-Turcotte-Pugh A; thrombocytopenic; non-genotype 3; and treatment 
experienced. HCC occurrence was observed in 46 individuals during follow-up. In univariate analysis, 
IFN-free receipt was associated with a significantly increased risk of HCC (HR: 2.48; P=0.021). 
However after multivariate adjustment for baseline factors, no significant risk attributable to IFN-free 
therapy persisted (aHR: 1.15, P=0.744).  
CONCLUSION: These findings suggest that the higher incidence of HCC following SVR with IFN-
free therapy relates to baseline risk factors/patient selection, and not the use of IFN-free therapy per 
se. 
LAY SUMMARY: We examined the risk of liver cancer among 857 patients with cirrhosis in 
Scotland who received hepatitis C antiviral therapy and achieved a cure. We compared the risk of 
first-time liver cancer in patients treated with the newest interferon-free regimens, to patients treated 
with interferon.  After accounting for the different characteristics of these two treatment groups, we 
found no evidence that interferon-free therapy is associated with a higher risk of liver cancer.  
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INTRODUCTION 
The arrival of interferon (IFN)-free direct acting antiviral (DAA) regimens from 2014-2015 has 
transformed the treatment of hepatitis C virus (HCV) infection. In addition to causing few adverse 
effects and being convenient to administer (i.e. with one tablet per day dosing for only 8-12 weeks), 
IFN-free therapy results in cure rates exceeding 90%, even in patients with advanced liver disease. 
[1,2] With IFN-based regimens, a cure is associated with a 81% (95% CI: 56-92), and 94% (95% CI: 
81-98) reduction in the risk of hepatocellular carcinoma (HCC) and liver mortality, respectively for 
patients with advanced fibrosis [3]. The relatively recent introduction of IFN-free therapy however, 
means that we do not yet know what the analogous value of an IFN-free cure is – i.e. whether it is 
better, worse or equivalent to an IFN-based cure (although the assumption thus far, for instance in 
cost effectiveness modelling work[4], has been one of equivalence).  
Recently, a number of European studies have described high rates of HCC occurrence and recurrence 
following receipt of IFN-free regimens.[5-8] Reig et al reported that of 58 patients from Spain with a 
complete radiological response to HCC, 16 (27.6%) developed HCC recurrence 5.7 months after 
receiving an IFN-free regimen. [5] Similarly, Conti et al reported that of 59 patients from Italy with a 
complete response to resection/ablation of HCC, 28.8% developed HCC recurrence 24 weeks after 
starting IFN-free treatment. [6] In terms of HCC occurrence, Conti et al report that 3.2% of 285 
cirrhotic patients developed HCC for the first time by 24 weeks after starting IFN-free therapy in 
Italy. [6]Another study from Portugal noted a similar rate of HCC occurrence (7.4% with HCC at 
twelve months after starting an IFN-free regimen). [7] Prima facie, this level of HCC recurrence and 
occurrence is higher than expected. For instance, data from the STORM trial following individuals 
after successful response to surgical resection/local ablation of HCC, reported ~15-20% HCC 
recurrence at six months [9]. Meanwhile, HCC occurrence in cirrhotic patients attaining a hepatitis C 
cure through pegylated interferon and ribavirin has ranged from 1.0-1.4% per annum. [10,11]  
Two theories have dominated the discussion of these findings thus far. Firstly, Reig et al and others 
have speculated that the rapid decline in hepatitis C viral load upon starting antiviral therapy, and the 
abrupt cessation of liver inflammation that results from this, may have the unintended consequence of 
adversely dampening cancer immune-surveillance activities that serve to identify and remove cancer-
prone hepatocytes. Individuals receiving IFN-free therapy may be particularly prone to this theoretical 
mechanism for HCC because the transition to undetectable viral load is far more rapid with IFN-free 
therapies relative to IFN-containing regimens, and/or because IFN has anti-proliferative and immune-
modulating properties that may offset any such immune surveillance down-regulation. [5] 
Alternatively, others have suggested that the higher risk of HCC reflects a shift in the case mix of 
individuals attaining a HCV cure post-IFN-free availability. [12] That is to say, patients treated and 
achieving sustained viral response (SVR) with IFN-free therapy may on average, have a greater pre-
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existing risk of HCC relative to those treated with IFN-containing regimens, making uncontrolled 
comparisons misleading.  
Data reporting the risk of HCC by treatment regimen from large and representative cohorts of cured 
HCV patients are needed to answer this important question. Thus, we herein used the well-
characterised Scottish Hepatitis C clinical database – a nationwide registry of HCV treatment patients 
- to identify cirrhotic patients attaining SVR in Scotland between 1997 and 2016. Our objective was to 
examine the incidence of de novo HCC occurrence according to the type of regimen received. In 
particular, we wanted to assess the credibility of the shifting case mix theory – that is whether 
differences in patient characteristics could account for the “higher” risk of HCC occurrence following 
receipt of IFN-free regimens versus IFN-containing regimens. 
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METHODS:  
DATA SOURCE: CLINICAL DATABASE AND MEDICAL CHART REVIEW 
We used data from the Scottish HCV clinical database, which consists of standalone Microsoft Access 
databases installed at 17/18 HCV treatment clinics across Scotland. Each database captures detailed 
clinical and epidemiological information on individuals who have attended an appointment for 
care/management of HCV infection [13,14].An anonymised extract of each database is downloaded 
annually by Health Protection Scotland and assembled into several nationwide datasets (at the time of 
this analysis, the latest extracts were complete up to May 2016).Patients on the clinical database have 
provided informed “opt-out” consent for use of their data in administrative and research purposes.  
In this study, key data from the clinical database were supplemented with a medical chart review 
carried out in February and March of 2017 by data entry staff and lead clinicians at participating 
clinics. This chart review entailed the retrieval and study of an individual’s medical records to obtain 
information on HCC occurrence, mortality events and relevant exposure variables, where that 
information was missing, or otherwise not available from the database at the time of the last 
download. The study protocol was approved by the Scottish HCV Clinical database monitoring 
committee. 
INCLUSION/EXCLUSION CRITERIA: 
This study included patients from the 12 Scottish HCV clinics, whose clinical database was complete 
at the time of the last download, and that were able to carry out the requisite medical chart review. 
Collectively, these 12 clinics account for circa 85% of all HCV treatment episodes occurring 
nationally in Scotland. We identified all individuals at these clinics who: (i) attained sustained viral 
response (SVR) between 1 Jan 1997 and 1 April 2016; and (ii) had received a diagnosis of liver 
cirrhosis prior to commencing therapy. We excluded patients with hepatitis B or HIV co-infection 
prior to treatment, or with HCC prior to starting treatment. An SVR was defined as testing viral RNA 
negative for a minimum of 12 or 24 weeks following completion of treatment, as per clinical 
guidelines. Up to 2014, the minimum time period required to establish SVR was exclusively 24 weeks 
(i,e. a SVR 24). From 2014, in keeping with changed clinical guidelines [15] reflecting strong 
concordance between SVR12 and SVR24 [16], SVR was defined as a negative test beyond 12 weeks 
post-treatment. 
PRIMARY OUTCOME EVENT:  
The primary outcome event was first time occurrence of HCC through to 31 Jan 2017 following 
commencement of antiviral therapy. We used the date of HCC diagnosis (i.e. date of the first cross-
sectional image meeting HCC diagnostic criteria [17], or, if performed, the date of biopsy diagnostic 
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of HCC) as a surrogate for time of HCC occurrence. HCC diagnoses in this cohort will have been 
triggered either through (i) symptomatic onset of HCC, or (ii) six-monthly abdominal ultrasound 
screening (which, as per best practice guidelines [17], is offered to all patients diagnosed with 
cirrhosis in Scotland).We identified all new post-treatment diagnoses of HCC through the clinical 
database and medical chart review. All cases identified were cross-checked against instances of HCC 
registered in the Scottish Cancer database –which, at the time of analysis, provided complete 
individual-level data on cancer incidence up until 31 Dec 2014 – to ensure no HCC events were 
missed. For each identified case of HCC, we sought via medical chart review, information on the 
number of HCC nodules; and the maximum HCC nodule diameter at the time of HCC diagnosis; this 
aspect of the chart review was completed by the lead clinician at the clinic where the individual(s) in 
question attained SVR. We also collected data on the last abdominal ultrasound screening test for 
HCC through to 1 August 2016 for all individuals in the cohort. 
PRIMARY EXPOSURE VARIABLE 
The primary exposure variable was the type of treatment regimen received- specifically whether the 
regimen included interferon, or whether the regimen was interferon-free. We also explored an 
alternative definition, whether or not the course of therapy included a DAA.  
DATA ON AND DEFINITIONS OF RELEVANT COVARIATES: 
Data on a wide range of baseline covariates were included in this analysis. These were as follows: 
age; gender; ethnicity; Child-Turcotte-Pugh (CTP) score; platelet count; alphafetoprotein; diabetes, 
alcohol use history; smoking; HCV transmission route; genotype; previous treatment history and 
deprivation status and clinic location. CTP score assigns each individual into one of three levels of 
cirrhosis severity (the least severe being level A, and the most severe being level C), based on pre-
treatment bilirubin, albumin, prothrombin time and the presence/absence of ascites and 
encephalopathy. For the bilirubin, albumin and prothrombin time components of this score, we used 
the most recent test carried out 0-90 days prior to treatment. Individuals who did not receive a 
prothrombin time test in this period were assumed to be CTP stage A if they did not have ascites or 
encephalopathy and had albumin level of >3.5g/dl, and bilirubin <2mg/dl (applying to 21.1% of the 
cohort). Information on platelet count, and alphafetoprotein were similarly based on the most recent 
test carried out 0-90 days prior to starting treatment. Thrombocytopenia was defined as a platelet 
count of <100 per 109/L. Clinic location was assessed in terms of whether the clinic attended was 
within or outside of the Greater Glasgow and Clyde (GGC) health board (the largest regional NHS 
board in Scotland with the greatest burden of diagnosed chronic HCV). Diabetes status referred to 
whether the patient had ever received a diagnosis of diabetes from a health professional. We defined a 
history of heavy alcohol use as consumption of more than 50 units of alcohol per week for six months 
or more, at any point in time. Previous treatment history refers to the number of treatment episodes 
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the patient had commenced prior to their eventual SVR. Data on mortality through to June 2016 were 
obtained via linkage to the Scottish mortality register, whilst mortality in the more recent period of 
June 2016-31 January 2017 was ascertained through the aforementioned medical chart review carried 
out by data entry staff in February-March 2017. Deprivation was measured through the Scottish Index 
of multiple deprivation (SIMD), which assigns a deprivation score to each address in Scotland. This 
SIMD score was obtained via an anonymised linkage to the Community Health Index database, which 
holds the address of each individual registered with a general practitioner in Scotland and maps that 
address to an SIMD score. For this analysis, we grouped the SIMD score into quintiles and compared 
outcomes in the two lower (i.e. two most deprived) quintiles to the three upper (i.e. most affluent) 
quintiles. All of these aforementioned data linkages were approved by the National Services Scotland 
Public Benefit Privacy Panel.  
STATISTICAL ANALYSES 
We adopted a survival analysis approach for this analysis. Follow-up time began at the treatment start 
date resulting in SVR, and ended at either: the date of HCC occurrence; the date of mortality, or 31 
January 2017 (which ever came first). We calculated the unadjusted and adjusted association between 
treatment regimen and HCC occurrence using Cox regression. For the adjusted association between 
treatment regimen and HCC, we controlled for all co-factors associated either with the outcome (i.e. 
HCC occurrence) or with the primary exposure (i.e. treatment regimen). For this we defined 
“association” conservatively as that demonstrating a p-value <0.1. We also fitted an interaction term 
between time-period (defined as before and after 24 weeks post-treatment completion) and HCC 
occurrence to assess the timing of HCC occurrence according to treatment regimen. Conformity to the 
proportional hazards assumption was assessed graphically and via the Schoenfeld residual test. 
SENSITIVITY ANALYSES: 
We carried out two one-way sensitivity analyses (SA). In SA-1 we additionally censored follow-up 
time at the date of last HCC screening attrition (if at all). The HCC screening attrition date was 
defined as date of the last ultrasound screening test plus 6 months, with 6 months referring to the 
recommended regularity of HCC screening for patients with cirrhosis[17]. In SA-2 we explored an 
alternative definition of treatment regimen; that being DAA-containing versus DAA-free. 
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RESULTS:  
DERIVATION OF FINAL COHORT. 
We identified 902 patients commencing treatment and attaining SVR between Jan 1997 and April 
2016, who were not co infected with either HIV or hepatitis B virus. From this initial cohort, we 
excluded 43 patients with a date of HCC diagnosis prior to their treatment start date. We also 
excluded all patients diagnosed with HCC after the onset of therapy if suspicion of their HCC 
predated the antiviral therapy start date (N=2, both with suspicious focal lesions on pre-treatment 
ultrasound, confirmed on MRI as HCC post treatment initiation). Our final sample therefore 
comprised 857 patients.  
DESCRIPTION OF COHORT AT BASELINE 
Approximately a third (31.7%) of the cohort were treated with an IFN-free regimen, whilst the 
remainder received an IFN-containing regimen. The most common IFN-free regimen received was 
sofosbuvir+ledipasvir±ribavirin (58.8%) followed by sofosbuvir+daclatasvir (16.2% - see eTable 1). 
Most patients treated with IFN-containing therapy received either pegylated interferon±ribavirin 
(47.4%), or pegylated interferon±ribavirin+sofosbuvir (38.1%). Patients treated with IFN-free therapy 
were different in many respects to patients treated with IFN-containing therapy. Specifically, those 
treated with an IFN-free regimen were more likely to have/be: older; of white ethnicity, CTP- B/C; 
thrombocytopenic; non-genotype 3; failed HCV treatment at least twice in the past; been treated 
outside of GGC (see Table 1).  
HCC OCCURRENCE DURING FOLLOW-UP: 
The median duration of follow-up was 2.4 years overall, but varied markedly by treatment regimen 
(1.7 and 3.5 year for IFN-free and IFN-containing recipients, respectively). Over this follow-up 
period, 46 cases of HCC occurrence were identified. Of these, 34 and 12 were treated with an IFN-
containing and IFN-free regimen, respectively. The crude rate of HCC occurrence was 1.45 events per 
100 person years (95% CI: 1.09-1.94). However, there was variation in this crude rate by treatment 
regimen; the event rate was 1.26 per 100 person-years for individuals treated with IFN-containing 
therapy, versus 2.53 for individuals treated with IFN-free therapy (see Table 2 and eFigure.1). Most 
cases of HCC occurrence (61%) comprised a single nodule. The median diameter of the largest HCC 
nodule was 2.6cm. No significant differences in the number of nodules or the maximum nodule size, 
were observed with respect to IFN-free versus IFN-containing regimens (see Table 3 and eTable.2).  
FACTORS ASSOCIATED WITH HCC OCCURRENCE. 
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In univariate analysis, individuals treated with an IFN-free regimen had a significantly higher risk of 
HCC occurrence relative to individuals treated with an IFN-containing regimen (HR: 2.48; 95% CI: 
1.14-5.37) – see Table 4. Other factors associated (at p-value <0.1) with an increased risk of HCC 
occurrence in univariate analysis were: increasing age; CTP-B/C; thrombocytopenia; alphafetoprotein 
≥10 ng/ml; failing HCV treatment at least twice in the past; and treatment outside of GGC  
The higher risk associated with IFN-free regimens in univariate analyses was considerably attenuated 
after multivariate adjustment (aHR:1.15; 95% CI: 0.49-2.71)- see Table 5. The two biggest 
contributors to this attenuation were adjustment for pre-treatment platelet count and CTP score (see 
Figure.1). The association between treatment regimen and HCC occurrence was consistent across 
time period with no suggestion of clustering by time (see Figure 2). Factors that were significantly 
associated in multivariate analysis with HCC occurrence at p<0.05 were: (i) age 50-59years vs 40-
49years (aHR:2.68; p=0.006); (ii) age 60+years vs 40-49 years (aHR:3.62;p=0.008); (iii) CTP-B/C Vs 
CTP-A (aHR:2.58; p=0.021); (iv) thrombocytopenia (aHR: 2.68; p=0.006); and (v) prior failure of 2+ 
courses of therapy (aHR: 2.52, p=0.041). No violations of the proportional hazards assumption were 
observed in either univariate or multivariate models.  
SENSITIVITY ANALYSES: 
In SA-1, more than half (55%) of the cohort were censored for HCC screening attrition (see eTable 3). 
The unadjusted association between regimen (IFN-free versus IFN-containing) and HCC was 
HR:2.82 (95% CI: 1.04-7.63). This association attenuated to HR: 1.28 (95% CI: 0.41-4.00) following 
full multivariate adjustment. Thus, the pattern of association between treatment regimen and HCC 
occurrence was similar between SA-1 and our basecase analysis (see eFigure.2). When defined in 
terms of DAA-containing versus DAA-free (SA2), treatment regimen was not associated with HCC 
occurrence, either at the univariate level (HR: 1.36; 95% CI: 0.66-2.79), or in multivariate analysis 
(aHR: 0.57; 95% CI: 0.24-1.40). 
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DISCUSSION 
PRINCIPLE FINDINGS:  
Recent studies from Europe have warned that the risk of HCC occurrence in cirrhotic individuals may 
be higher after attaining an IFN-free hepatitis C cure versus an IFN-containing cure. [6-8] Although 
this finding could have major implications for the treatment of HCV, the studies on which it was 
predicated did not carry out multivariate adjustment for confounding factors, and involved small 
sample sizes only. In the present study, our aim was to investigate the issue of HCC occurrence by 
treatment regimen more robustly using data from the Scottish clinical database – a large unselected 
nationwide cohort of individuals treated for chronic hepatitis C infection. Of 857 cirrhotic patients 
attaining SVR between 1997-2016, we did find, prima facie, a 2.5 fold higher risk of HCC occurrence 
among patients receiving an IFN-free regimen compared to an IFN-containing regimen (HR: 2.48; 
95% CI: 1.14-5.37). Yet, as noted previously elsewhere [12,18], the baseline characteristics of 
individuals with an IFN-free cure were demonstrably different from those with an IFN-containing 
cure. Specifically, patients with an IFN-free cure were more likely to: be older; have a CTP score of 
B/C versus A; be thrombocytopenic; and be treatment experienced. A major finding from this study 
therefore, is that upon adjusting for these differences (in particular differences in CTP score and 
platelet count – see Figure.1), the elevated risk of HCC associated with IFN-free regimens was almost 
entirely attenuated (aHR:1.15; 95% CI: 0.49-2.71). This would tend to indicate that the higher risk of 
HCC occurrence among individuals receiving IFN-free therapy is a reflection of the shifting patient 
case mix, as opposed to the pharmacodynamics of IFN-free therapy or any other direct or indirect 
consequence of IFN-free therapy itself.  
COHERENCE WITH PREVIOUS WORK: 
The initial studies suggesting a higher risk of HCC occurrence following a IFN-free cure versus an 
IFN-containing cure [6-8] entailed small sample sizes and did not perform multivariate regression 
against a suitable control group. The present study is consistent with these initial data however, 
insofar as we too, before multivariate adjustment, found an increased risk of HCC occurrence among 
patients receiving IFN-free therapy. Yet, this study advances that initial work by reporting 
considerable attenuation in that “higher” risk after adjustment for relevant confounding factors. Our 
findings are also consistent with recent work by Cheung et al from England. [19] This study reported 
that, of 406 patients with decompensated cirrhosis treated with IFN-free therapies, HCC occurred in 
4.2% of patients during the first six months from commencing treatment. Although this incidence, at 
first glance, is high (at least in respect to individuals receiving a IFN-containing cure[9,10]), it was 
nevertheless equivalent to occurrence seen in a matched control group comprising untreated patients 
at a comparable disease stage. Thus, similar to this present study, Cheung et al found no evidence for 
an elevated risk of HCC occurrence following IFN-free treatment after benchmarking against an 
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appropriate control group (albeit this study is likely to suffer from the same limitations around HCC 
surveillance as outlined for this study; see strength and limitations paragraph).  
STRENGTHS AND LIMITATIONS: 
A significant strength of this study is that it robustly addresses a very topical issue, of major 
importance to patients with HCV and the field of HCV treatment in general. A second strength is that 
our cohort comprises a majority (c.85%) of cured patients in Scotland. In contrast, previous studies 
examining this question [5-8] were confined to patients attending a smaller number of potentially 
select clinics and may not have been representative of the wider treated/cured population. This study 
has several limitations however. Firstly, although our study is one of the largest to-date to examine the 
risk of HCC occurrence according to IFN-free versus IFN-containing regimens, our sample size may 
nevertheless still be inadequate to detect a difference in the risk of HCC by regimen, if that difference 
was small. Secondly, whilst six-monthly abdominal ultrasound examinations were offered to all 
patients in this cohort, the uptake of this offer was suboptimal. SA-1 indicates that at least 55% of our 
cohort had missed a six monthly ultrasound exam at least once during follow-up. This poor 
compliance has been found in other settings too [20], however the issue did not affect our headline 
results – i.e. the pattern of association between regimen and HCC after including additional censoring 
for screening attrition was no different to our base-case result (see eFigure.2). Indeed, even though 
adherence to HCC surveillance is suboptimal, most HCC patients will present anyway with 
symptomatic disease within a relatively short timeframe if not identified through screening; as such 
one would not necessarily expect this limitation to cause appreciable bias. Another issue is that 
patients were not necessarily screened for HCC at time zero (i.e. at the point of starting antiviral 
therapy). Thus, we cannot be absolutely certain that the incident HCC cases identified in our cohort 
weren’t already present at the time of starting antiviral therapy. However, we did exclude all cases of 
HCC that were diagnosed prior to antiviral therapy, and further excluded all cases diagnosed after 
antiviral therapy if suspicion of that HCC predated treatment onset. Fourthly, a diagnosis of liver 
cirrhosis was a key eligibility condition for this study. Over the time frame of this study, a cirrhosis 
diagnosis would typically have been made through a combination of: (i) liver biopsy; (ii) transient 
elastography; (iii) abdominal ultrasound; (iv)clinical examination and (v) routine liver function tests. 
However, a further limitation of this study is that we lacked data to describe the exact 
modality/combination of modalities used to make this diagnosis. Fifthly our study only examined the 
risk of HCC occurrence, and not of HCC recurrence. The null association noted here between an IFN-
free cure and HCC occurrence, doesn’t in itself rule out an association between an IFN-free cure and 
HCC recurrence. Although one recent study entailing controlled comparisons from three prospective 
French cohorts, has recently cast doubt on this association too. [21] Finally, inclusion in this study 
required a diagnosis of SVR, meaning that study participants must have survived the time interval 
between starting treatment and eligibility for SVR 12/SVR 24 assessment.  Treatment responders who 
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developed HCC during treatment and died soon after would have been excluded from this study if 
they did not live long enough to demonstrate SVR; our methods therefore may have missed a small 
number of patients with rapidly progressive disease. Patients with HCC may be less likely to achieve 
an SVR [22], and examination of risk of HCC per regimen, independent of  SVR would be an 
alternative approach. The manpower required to conduct casenote review of the large numbers of 
historic treatment failures, together with the small number of treatment failures with DAAs, made this 
approach impractical. In addition, assumed equivalence with IFN achieved SVR underpins the 
rationale and cost effectiveness for treatment with DAAs, making  testing this assumption of vital 
importance. 
CONCLUSIONS: 
This study, based on data from a large and representative sample of cured hepatitis C patients in 
Scotland, suggests that the higher risk of HCC occurrence following receipt of IFN-free therapies 
reflects a change in patient case mix, as opposed to the direct or indirect consequences of IFN-free 
therapy per se. However, further data from other large cohorts should be sought to confirm these 
findings.  
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FIGURE LEGENDS  
FIGURE 1: Association between interferon-free therapy (versus interferon-containing) and HCC 
occurrence, according to level of covariate adjustment. Partial adjustment refers to adjustment for: 
age, Child-Turcotte-Pugh score, thrombocytopenia, and number of prior treatment episodes. Full 
adjustment refers to adjustment for: age, gender, ethnicity, Child –Turcotte-Pugh score, 
thrombocytopenia, alphafetoprotein, genotype, number of prior treatment episodes, and clinic location 
FIGURE 2: Fig.2: Association between interferon-free therapy (versus interferon-containing) and 
HCC occurrence, by time period. Partial adjustment refers to adjustment for: age, Child-Turcotte-
Pugh score, thrombocytopenia, and number of prior treatment episodes. Full adjustment refers to 
adjustment for: age, gender, ethnicity, Child –Turcotte-Pugh score, thrombocytopenia, 
alphafetoprotein, genotype, number of prior treatment episodes, and clinic location 
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No (N=585) Yes (N=272)
Number (col%*) Number (col%*) Number (col%*)
<40 87 (14.9) 17 (6.3) 104 (12.1)
40-49 268 (46.0) 105 (38.6) 374 (43.6)
50-59 179 (30.6) 102 (37.5) 281 (32.8)
60+ 50 (8.6) 48 (17.7) 98 (11.4)
Age, mean 48.1 (8.1) 52.1 (8.6) 49.4 (8.5) <0.001†
Female 134 (22.9) 78 (28.7) 212 (24.7)
Male 451 (77.1) 194 (71.3) 645 (75.3)
White 530 (90.6) 261 (96.0) 791 (92.3)
Asian/other 55 (9.4) 11 (4.0) 66 (7.7)
quintiles 1-2 (i.e. bottom 40%) 408 (70.7) 187 (69.5) 595 (70.3)
quintils 3-5 (i.e. top 60%) 169 (29.3) 82 (30.5) 251 (29.7)
Unknown 8(-) 3 (-) 11 (-)
A 420 (90.5) 133 (69.6) 553 (84.4)
B/C 44 (9.5) 58 (30.4) 102 (15.6)
Unknown 121 (-) 81 (-) 202 (-)
No 415 (77.9) 153 (60.7) 568 (72.4)
Yes 118 (22.1) 99 (39.3) 217 (27.6)
Unknown 52 (-) 20 (-) 72 (-)
152.3 (64.1) 131.2 (72.9) 145.6 (67.7) <0.001‡
<10 277 (78.0) 125 (72.7) 402 (76.3)
≥10 78 (22.0) 47 (27.3) 125 (23.7)
Unknown 230 (-) 100 (-) 330 (-)
9.6 (18.1) 10.9 (18.6) 10.1 (18.3) 0.875 ‡
No 515 (90.4) 250 (92.3) 765 (91.0)
Yes 55 (9.7) 21 (7.8) 76 (9.0)
Unknown 15 (-) 1 (-) 16 (-)
No 288 (57.5) 121 (52.8) 409 (56.0)
Yes 213 (42.5) 108 (47.2) 321 (44.0)
Unknown 84 (-) 43 (-) 127 (-)
No 123 (28.3) 52 (25.5) 175 (27.4)
Yes 311 (71.7) 152 (74.5) 463 (72.6)
Unknown 151 (-) 68 (-) 219 (-)
IDU 351 (70.3) 163 (70.3) 514 (70.3)
non-IDU 148 (29.7) 69 (29.7) 217 (29.7)
Unknown 86 (-) 40 (-) 126 (-)
3 375 (64.3) 73 (27.2) 446 (52.6)
non-3 208 (35.7) 195 (72.8) 403 (47.4)
unknown 2 (-) 4 (-) 6 (-)
0 424 (72.5) 130 (47.8) 554 (64.6)
1 122 (20.9) 96 (35.3) 218 (25.4)
2+ 39 (6.7) 46 (16.9) 85 (9.9)
Within Greater Glasgow and Clyde 409 (69.9) 162 (59.6) 571 (66.6)
Outwith Greater Glasgow and Clyde 176 (30.1) 110 (40.4) 286 (33.4)
* The Col % excludes unknowns where an unknown category exists . For continuous variables the standard deviation is shown as column % is not applicable
† p-value generated via a t-test; ‡p-value generated via a Wilcoxon rank sum test. 
N.B. p-values were generated via a Chi-squared test unless indicated otherwise. We excluded "unknown" categories from this test where an "unknown" category existed
Treatment data Number of prior 
treatment episodes
<0.001
Table 1: Characteristics  of final cohort, according to treatment regimen received 
Current smoker at first 
clinic appointment
0.452
Risk group 0.982
Virology data HCV genotype <0.001
Alphafetoprotein 
category , ng/ml
0.175
Alphafetoprotein, ng/ml, mean
Comorbidities/health 
behaviours
Diabetes present at 
treatment
TOTAL (N=857)
0.369
History of heavy 
alcohol use at first 
clinic appointment
0.241
Pre-treatment Liver 
disease markers
Child-Turcotte-Pugh  
score
<0.001
Thrombocytopenia <0.001
Platelet count, 109/L , mean
Geographical factors Clinic location 0.003
Variable category Variable IFN-free regimen
p-value**
Socio-demographic 
factors
Age category, years <0.001
Gender 0.068
Ethnicity 0.006
Deprivation quintile of 
resident address
0.723
  
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Description of follow-up (FU) data and outcome events, by treatment regimen received
No Yes
585 272 857
2697 475 3173
Median 3.5 1.7 2.4
Mean 4.6 1.7 3.7
Total number of events 34 12 46
no occuring <24 weeks post-treatment 6 5 11
no occuring 24+weeks post-treatment 28 7 35
mean time to event 3.4 1.0 2.8
median time to event 2.5 0.9 2.0
minimum time to event 0.3 0.47 0.3
maximum time to event 8.5 2.0 8.5
1.3 (0.9-1.8) 2.5 (1.4-4.4) 1.4 (1.1-1.9)Crude outcome rate, per 100 person years (95% CI)
All regimensIFN-free regimen
Number of outcome events 
(i.e. HCC occurences)
Time to ouctome event, 
person years
Total persons
Total person years follow-up
Average person years per 
patient
No Yes
1 17 (56.7) 8 (72.7) 25 (61.0)
2 8 (26.7) 1 (9.1) 9 (22.0)
≥3 5(16.7) 2 (18.2) 7 (17.1)
Mean 3.3 2.6 3.1
Median 2.7 2.1 2.6
* p-value generated using the Fisher's exact  test ; † p-value generated using the Wilcoxon rank sum test
N.B. data for number of nodules and nodule size missing in 5 cases
Maximum HCC nodule 
diameter, cm
0.54*
Table 3: Number of nodules and maximum nodule size for cases of HCC at the time of 
diagnosis, by treatment regimen received
Total number of HCC 
nodules, n(col%)
0.61†
IFN-free regimen All P-value
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Variable category Number (col%) HCC 
occurrence
Univariate hazard ratio 
(95% CI)
p-value*
No 585 (68.3) 34 REF (1.00) \
Yes 272 (31.7) 12 2.48 (1.14-5.37) 0.021
<40 104 (12.1) 1 0.20 (0.03-1.56) 0.125
40-49 374 (43.6) 13 REF (1.00) \
50-59 281 (32.8) 24 2.75 (1.40-5.41) 0.003
60+ 98 (11.4) 8 3.31 (1.37-8.02) 0.008
Female 212 (24.7) 8 REF (1.00) \
Male 645 (75.3) 38 1.59 (0.74-3.41) 0.232
White 791 (92.3) 43 REF (1.00) \
Asian/other 66 (7.7) 3 0.68 (0.21-2.19) 0.515
quintiles 1-2 (i.e. bottom 40%) 595 (70.3) 29 REF (1.00) \
quintils 3-5 (i.e. top 60%) 251 (29.7) 17 1.16 (0.63-2.12) 0.631
Unknown 11 (-) 0 \ \
A 553 (84.4) 20 REF (1.00)
B/C 102 (11.9) 14 5.24 (2.63-10.46) <0.001
Unknown 202 (-) 12 1.55 (0.76-3.18) 0.231
No 568 (66.3) 18 REF (1.00) \
Yes 217 (25.3) 24 3.96 (2.14-7.30) <0.001
Unknown 72 (-) 4 1.26 (0.42-3.74) 0.677
<10 402 (76.3) 19 REF (1.00)
≥10 125 (14.6) 13 2.26 (1.11-4.58) 0.024
Unknown 330 (-) 14 0.77 (0.39-1.54) 0.462
No 765 (89.3) 39 REF (1.00) \
Yes 76 (8.9) 7 1.51 (0.67-3.39) 0.315
Unknown 16 (-) 0 \ \
No 409 (56.0) 17 REF (1.00) \
Yes 321 (44.0) 20 1.47 (0.77-2.81) 0.244
Unknown 127 (-) 9 1.71 (0.76-3.83) 0.196
No 175 (27.4) 9 REF (1.00) \
Yes 463 (72.6) 23 1.05 (0.49-2.28) 0.897
Unknown 219 (-) 14 1.30 (0.56-3.01) 0.535
IDU 514 (70.3) 23 REF (1.00) \
non-IDU 217 (29.7) 15 1.37 (0.72-2.64) 0.340
Unknown 126 (-) 8 1.49 (0.67-3.34) 0.329
3 446 (52.6) 28 REF (1.00) \
non-3 403 (47.4) 17 0.88 (0.48-1.61) 0.677
unknown 6 (-) 1 2.37 (0.32-17.54) 0.397
0 554 (64.6) 28 REF (1.00) \
1 218 (25.4) 10 1.44 (0.69-3.01) 0.336
2+ 85 (9.9) 8 3.52 (1.56-7.95) 0.002
Within Greater Glasgow and Clyde 571 (66.6) 21 REF (1.00)
Outwith Greater Glasgow and Clyde 286 (33.4) 25 2.01 (1.12-3.61) 0.020
* p-value generated via the wald test
Virology data HCV genotype
Child-Turcotte-Pugh score
Thrombocytopenia
Alphafetoprotein category , 
ng/ml
Comorbidities/health 
behaviours
History of heavy alcohol use 
at first clinic appointment
Current smoker at first clinic 
appointment
Geographical factors Clinic location
Variable
Table 4: Factors associated with occurrence of HCC: univariate  analysis
Age category, years
Risk group
Diabetes present at treatment
IFN-free regimen
Socio-demographic 
factors
Gender
Ethnicity
Deprivation quintile
Primary exposure 
variable
Treatment data Number of prior treatment 
episodes
Pre-treatment Liver 
disease markers
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Variable category Adjusted hazard ratio 
(95% CI)
p-value*
No REF (1.00) \
Yes 1.15 (0.49-2.71) 0.744
<40 0.18 (0.02-1.36) 0.096
40-49 REF (1.00) \
50-59 2.68 (1.33-5.37) 0.006
60+ 3.62 (1.41-9.30) 0.008
Female REF (1.00) \
Male 1.71 (0.78-3.74) 0.183
White REF (1.00) \
Asian/other 0.33 (0.09-1.18) 0.089
A REF (1.00) \
B/C 2.58 (1.16-5.76) 0.021
Unknown 1.45 (0.63-3.30) 0.382
No REF (1.00) \
Yes 2.68 (1.32-5.45) 0.006
Unknown 1.42 (0.40-4.96) 0.586
<10 REF (1.00) \
≥10 1.59 (0.74-3.39) 0.289
Unknown 0.90 (0.42-1.90) 0.775
3 REF (1.00)
non-3 0.65 (0.33-1.26) 0.202
unknown 3.90 (0.47-32.07) 0.205
0 REF (1.00) \
1 1.39 (0.64-3.02) 0.407
2+ 2.52 (1.04-6.13) 0.041
Within Greater Glasgow and Clyde REF (1.00) \
Outwith Greater Glasgow and Clyde 1.61 (0.88-2.96) 0.126
* p-value generated via the wald test
Table 5: Factors associated with occurrence of HCC: multivariate analysis
Variable
Primary exposure 
variable
IFN-free regimen
Socio-demographic 
factors
Age category, years
Gender
Ethnicity
Pre-treatment Liver 
disease markers
Child-Turcotte -Pugh  score
Thrombocytopenia
Alphafetoprotein category , 
ng/ml
Geographical factors Clinic location
Virology data HCV genotype
Treatment data Number of prior treatment 
episodes
  
23 
 
  
  
24 
 
HIGHLIGHTS:  
• Crude risk of HCC higher for IFN-free recipients than IFN-containing recipients 
• IFN-free and IFN-containing recipients differ with respect to confounding factors  
• Association between IFN-free therapy and HCC disappears after adjusting for baseline 
confounders 
• At HCC diagnosis, no differences in nodule size or nodule number were apparent by regimen 
(albeit numbers were small).  
 
 
 
 
 
